Diabetic Nephropathy, Essential Hypertension, Type 2 Diabetes Mellitus
Conditions
Brief summary
The detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ACE), angiotensin II receptor blocker (ARB) or a combination of both. Recent evidence has provided robust evidence that aldostrone escape plays an important role in this regard. It is believed that aldostrone escape occurs quite commonly with reports indicating prevalence rates as high as 22% with ARBs and 40% with ACE inhibitors. In a trial of patients with diabetes and hypertension it was shown that treatment of aldostrone escape with spironolactone 25 mg daily for three months significantly reduces proteinuria. A number of other trials have similarly observed that addition of spironolactone to an ACE inhibitor based regimen provides additional benefits on proteinuria reduction, blood pressure control, and prevention of glomerular filtration rate (GFR) decline. Most of the available trials in this regard are of short duration (e.g. three months), and have added spironolactone to an ACE or ACE+ARB based regimen (the so-called triple blockade). Currently, evidence evaluating efficacy of a combined ARB+spironolactone regimen compared with conventional double RAS blockade (i.e. ACE+ARB) is lacking. Hence, this randomized open label trial was initiated to determine the effects of addition of spironolactone 25 mg daily to losartan over a period of 18 months.
Interventions
DRUGspironolacone 25 mg tablets added to losartan
spironolactone 25 mg once daily added to losartan
Sponsors
Tehran University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria * treatment with combination of enalapril and losartan for more than one year
Exclusion criteria
* history of non-adherence to prescribed medication assessed by the prescribing physician * baseline potassium \> 5.5 meq/L * chronic kidney disease stages 4 or 5 * history or evidence of non-diabetic kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary albumin excretion | 18 months | Urinary albumin excretion assessed by overnight (12 hour) collection of urine. Measured at baseline, 3rd month, 6th month, 9th month, 12th month, 15th month, and 18th month. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| estimated glomerular filtration rate | 18 months | estimated glomerular filtration rate calculated using the formula developed by Chronic Kidney Disease Epidemiology Collaboration. Measured at baseline, 3rd month, 6th month, 9th month, 12th month, 15th month, and 18th month. |
| Blood pressure | 18 months | Systolic and diastolic blood pressure assessed by mercury sphygnomanometry. Patients were placed in a sitting position and after ten minutes rest, two readings from right-side hand with five minutes interval were obtained. Measured at baseline, 3rd month, 6th month, 9th month, 12th month, 15th month, and 18th month. |
| serum creatinine concentrations | 18 months | serum creatinine concentrations assessed by Jaffe method. Measured at baseline, 3rd month, 6th month, 9th month, 12th month, 15th month, and 18th month. |
| Serum potassium concentrations | 18 months | Serum potassium concentrations measured at baseline, 1st month, 3rd month, 6th month, 9th month, 12th month, 15th month, and 18th month. |
Countries
Iran
Outcome results
None listed